PHAT RSI Chart
Last 7 days
-9.9%
Last 30 days
17.9%
Last 90 days
33.3%
Trailing 12 Months
0.3%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 08, 2024 | henderson molly | sold | -38,128 | 11.1 | -3,435 | cfo and cbo |
Mar 22, 2024 | curran terrie | sold | -153,513 | 9.11 | -16,851 | president and chief executive |
Jan 24, 2024 | takeda pharmaceutical co ltd | sold | -30,000,000 | 8.1 | -3,703,700 | - |
Jan 19, 2024 | henderson molly | sold | -48,900 | 7.7533 | -6,307 | cfo and cbo |
Nov 20, 2023 | henderson molly | sold | -15,402 | 7.2415 | -2,127 | cfo and cbo |
Nov 08, 2023 | parikh asit | bought | 19,500 | 7.8 | 2,500 | - |
Nov 07, 2023 | parikh asit | bought | 31,040 | 7.76 | 4,000 | - |
Nov 06, 2023 | parikh asit | bought | 8,040 | 8.04 | 1,000 | - |
Nov 01, 2023 | henderson molly | acquired | - | - | 22,500 | cfo and cbo |
Nov 01, 2023 | nabulsi azmi | acquired | - | - | 32,500 | chief operating officer |
Which funds bought or sold PHAT recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Apr 12, 2024 | INSPIRION WEALTH ADVISORS, LLC | unchanged | - | 50,944 | 373,123 | 0.06% |
Apr 05, 2024 | GAMMA Investing LLC | added | 228 | 197 | 244 | -% |
Apr 05, 2024 | CWM, LLC | new | - | - | - | -% |
Mar 28, 2024 | Newbridge Financial Services Group, Inc. | sold off | -100 | -363 | - | -% |
Mar 22, 2024 | PNC FINANCIAL SERVICES GROUP, INC. | added | 3.85 | -115 | 1,233 | -% |
Mar 11, 2024 | VANGUARD GROUP INC | added | 1.76 | -2,075,810 | 17,862,200 | -% |
Mar 08, 2024 | ICA Group Wealth Management, LLC | new | - | 11,869 | 11,869 | -% |
Mar 01, 2024 | GOLDMAN SACHS GROUP INC | added | 203 | 2,402,210 | 3,838,450 | -% |
Feb 28, 2024 | AMERICAN INTERNATIONAL GROUP, INC. | added | 3.43 | -14,277 | 145,514 | -% |
Feb 16, 2024 | GSA CAPITAL PARTNERS LLP | sold off | -100 | -1,264,000 | - | -% |
Unveiling Phathom Pharmaceuticals Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Phathom Pharmaceuticals Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 39.7B | 6.8B | -8.42 | 5.79 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 18.6B | 1.8B | -42.25 | 10.17 | ||||
BMRN | 17.3B | 2.4B | 103 | 7.14 | ||||
INCY | 12.0B | 3.7B | 20.07 | 3.25 | ||||
MID-CAP | ||||||||
APLS | 6.2B | 396.6M | -11.74 | 15.65 | ||||
BBIO | 4.5B | - | -6.94 | 60.35 | ||||
AXSM | 3.2B | 270.6M | -13.52 | 11.95 | ||||
ARWR | 3.0B | 240.7M | -10.03 | 12.36 | ||||
ACAD | 2.8B | 726.4M | -45.41 | 3.83 | ||||
SMALL-CAP | ||||||||
CPRX | 1.8B | 398.2M | 25.42 | 4.56 | ||||
NVAX | 576.6M | 983.7M | -1.06 | 0.59 | ||||
CRBP | 448.6M | 881.7K | -10.06 | 466.16 | ||||
INO | 256.8M | 4.9M | -1.9 | 52.78 | ||||
IBIO | 6.7M | 2.1M | -0.25 | 2.14 |
Phathom Pharmaceuticals Inc News
Balance Sheet | ||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2018Q4 |
Assets | 74.6% | 414 | 237 | 265 | 144 | 165 | 202 | 214 | 149 | 189 | 228 | 215 | 246 | 295 | 231 | 252 | 264 | 257 | 80.00 | - |
Current Assets | 75.3% | 397 | 227 | 258 | 140 | 161 | 198 | 209 | 146 | 187 | 225 | 211 | 243 | 291 | 227 | 249 | 262 | 256 | 78.00 | 1.00 |
Cash Equivalents | 78.5% | 381 | 214 | 249 | 130 | 155 | 197 | 207 | 138 | 183 | 225 | 210 | 238 | 287 | 226 | 247 | 257 | 244 | 74.00 | 1.00 |
Inventory | 988.3% | 1.00 | 0.00 | 0.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net PPE | 8.6% | 2.00 | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.00 | 0.00 | - |
Liabilities | 91.0% | 487 | 255 | 247 | 234 | 240 | 228 | 221 | 111 | 117 | 125 | 82.00 | 82.00 | 101 | 75.00 | 64.00 | 55.00 | 29.00 | 232 | - |
Current Liabilities | 61.7% | 39.00 | 24.00 | 22.00 | 14.00 | 26.00 | 23.00 | 21.00 | 11.00 | 19.00 | 28.00 | 40.00 | 41.00 | 56.00 | 28.00 | 13.00 | 5.00 | 4.00 | 207 | 2.00 |
Long Term Debt | -100.0% | - | 99.00 | 98.00 | 97.00 | 95.00 | 94.00 | 92.00 | 91.00 | 90.00 | 88.00 | 37.00 | 36.00 | 40.00 | 41.00 | 45.00 | 46.00 | 23.00 | 23.00 | - |
LT Debt, Current | - | - | - | - | - | - | - | - | - | - | - | 10.00 | 12.00 | 7.00 | 6.00 | 1.00 | - | - | - | - |
LT Debt, Non Current | 38.9% | 138 | 99.00 | 98.00 | 97.00 | 95.00 | 94.00 | 92.00 | 91.00 | 90.00 | 88.00 | 37.00 | 36.00 | 40.00 | 41.00 | 45.00 | - | 23.00 | - | - |
Shareholder's Equity | -Infinity% | -72.76 | - | 18.00 | - | -74.81 | - | - | 38.00 | 72.00 | 103 | 132 | 164 | 194 | 156 | 188 | 209 | 228 | - | - |
Retained Earnings | -9.4% | -928 | -849 | -805 | -764 | -727 | -672 | -620 | -570 | -529 | -493 | -456 | -420 | -385 | -331 | -297 | -276 | -256 | -158 | -1.29 |
Additional Paid-In Capital | 3.0% | 856 | 831 | 823 | 675 | 652 | 646 | 614 | 608 | 602 | 597 | 589 | 585 | 580 | 488 | 486 | 485 | 484 | 6.00 | 0.00 |
Shares Outstanding | 2.0% | 58.00 | 57.00 | 57.00 | 44.00 | 41.00 | 38.00 | 38.00 | 38.00 | 31.00 | 37.00 | 36.00 | 36.00 | - | - | - | - | - | - | - |
Float | - | - | - | - | - | - | - | 198 | - | - | - | 684 | - | - | - | 552 | - | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | -37.2% | -43,797 | -31,914 | -22,200 | -39,669 | -41,041 | -35,016 | -25,716 | -44,757 | -41,262 | -29,066 | -28,364 | -49,765 | -28,200 | -20,727 | -9,344 | -11,417 | -23,384 | -7,108 | -5,211 | -807 | - |
Share Based Compensation | 300.4% | 24,584 | 6,140 | 7,253 | 7,048 | 6,657 | 5,816 | 5,885 | 5,775 | 4,338 | 4,419 | 4,237 | 3,818 | 2,379 | 2,070 | 828 | 563 | - | - | - | - | - |
Cashflow From Investing | 49.4% | -475 | -939 | -6.00 | -214 | -412 | -134 | -428 | -67.00 | -100 | -14.00 | -45.00 | -169 | -124 | -183 | -57.00 | -676 | - | - | - | - | - |
Cashflow From Financing | 1630615.4% | 211,993 | 13.00 | 141,502 | 14,072 | - | 24,596 | - | - | 163 | 44,029 | 104 | 412 | 89,459 | - | - | 25,000 | 192,771 | -1,299 | - | - | - |
Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 12 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
Gross Profit [Abstract] | ||
Product revenue, net | $ 682 | $ 0 |
Cost of revenue | 167 | 0 |
Gross Profit | 515 | 0 |
Operating expenses: | ||
Research and development (includes related party amounts of $760 and $2,123, respectively) | 49,899 | 71,441 |
Selling, general and administrative (includes related party amounts of $55 and $0, respectively) | 117,928 | 100,999 |
Total operating expenses | 167,827 | 172,440 |
Loss from operations | (167,312) | (172,440) |
Other income (expense): | ||
Interest income | 7,876 | 2,132 |
Interest expense | (41,968) | (27,305) |
Other (expense), net | (188) | (110) |
Total other expense | (34,280) | (25,283) |
Net loss and comprehensive loss | $ (201,592) | $ (197,723) |
Net loss per share, basic | $ (3.93) | $ (5.05) |
Net loss per share, diluted | $ (3.93) | $ (5.05) |
Weighted-average shares of common stock outstanding, basic | 51,289,092 | 39,118,215 |
Weighted-average shares of common stock outstanding, diluted | 51,289,092 | 39,118,215 |
Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 381,393 | $ 155,385 |
Prepaid expenses and other current assets | 13,194 | 5,127 |
Accounts receivable, net | 1,637 | 0 |
Inventory | 1,208 | 0 |
Total current assets | 397,432 | 160,512 |
Property, plant and equipment, net | 2,146 | 1,207 |
Operating lease right-of-use assets | 1,475 | 2,287 |
Restricted cash | 2,863 | 505 |
Inventory, noncurrent | 8,234 | 0 |
Other long-term assets | 1,692 | 299 |
Total assets | 413,842 | 164,810 |
Current liabilities: | ||
Accounts payable (including related party amounts of $25 and $35 respectively) | 12,601 | 9,997 |
Accrued expenses (including related party amountsof $2,694 and $2,499 respectively) | 17,197 | 14,678 |
Accrued interest | 1,146 | 854 |
Operating lease liabilities, current | 726 | 708 |
Current portion of revenue interest financing liability | 7,111 | 0 |
Total current liabilities | 38,781 | 26,237 |
Long-term debt, net of discount | 137,842 | 95,264 |
Revenue interest financing liability | 299,816 | 109,525 |
Operating lease liabilities | 462 | 1,098 |
Other long-term liabilities | 9,700 | 7,500 |
Total liabilities | 486,601 | 239,624 |
Commitments and contingencies (Note 4) | ||
Stockholders' deficit: | ||
Preferred stock, $0.0001 par value; authorized shares - 40,000,000 at December 31, 2023 and December 2022; no shares issued and outstanding at December 31, 2023 and December 2022 | ||
Common stock, $0.0001 par value; authorized shares - 400,000,000 at December 31, 2023 and December 2022; issued shares - 57,970,044 and 41,723,308 at December 31, 2023 and December 2022, respectively; outstanding shares - 57,970,044 and 41,468,871 at December 31, 2023 and December 2022, respectively | 5 | 3 |
Treasury stock - 19 shares at December 31, 2023 and December 2022 respectively | 0 | 0 |
Additional paid-in capital | 855,921 | 652,276 |
Accumulated deficit | (928,685) | (727,093) |
Total stockholders' deficit | (72,759) | (74,814) |
Total liabilities and stockholders' deficit | $ 413,842 | $ 164,810 |